Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics

Clinical Nutrition

Volumn 30, Issue 5, 2011, Pages 616-623

  Cuerda, Cristina ^a   Merchan Naranjo, Jessica ^a   Velasco, Cristina ^a   Gutierrez, Alberto ^a   Leiva, Marta ^a   de Castro, Maria J ^a   Parellada, Mara ^a   Giráldez, Marisa ^a   Bretón, Irene ^a   Camblor, Miguel ^a   García Peris, Pilar ^a   Dulín, Elena ^a   Sanz, Inmaculada ^a   Desco, Manuel ^a   Arango, Celso ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Adiponectin; Adolescents; Antipsychotics; Metabolic side effects; Resting energy expenditure; Weight gain

Indexed keywords

ADIPONECTIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BIOENERGY; BODY COMPOSITION; BODY FAT; BODY MASS; CALORIMETRY; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; ENERGY EXPENDITURE; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MONOTHERAPY; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REST; SCHOOL CHILD; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADIPONECTIN; ADOLESCENT; ADOLESCENT DEVELOPMENT; ANTIPSYCHOTIC AGENTS; BASAL METABOLISM; BENZODIAZEPINES; BIOLOGICAL MARKERS; BODY COMPOSITION; CHILD; COHORT STUDIES; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; PROSPECTIVE STUDIES; RISPERIDONE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80053625345     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2011.03.007     Document Type: Article

References (57)

1. Aparasu R.R., Bhatara V. Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006, 57:1693.
2. Weinbrenner S., Assion H.J., Stargardt T., Busse R., Juckle G., Gericke C.A. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2009, 42:66-71.
3. Rani F., Murray M.L., Byrne P.J., Wong I.C.K. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008, 121:1002-1009.
4. Kalverdijk L.J., Tobi H., van den Berg P.B., Buiskool J., Wagenaar L., Minderaa R.B., et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 2008, 59:554-560.
5. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsichotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a metaanalysis of randomized controlled trials. Schizophr Res 1999, 35:51-68.
6. Lewis S., Lieberman J. CATIE and CUtLASS: can we handle the truth?. B J Psych 2008, 192:161-163.
7. Carpenter W.T., Buchanan R.W. Lessons to take home from CATIE. Psychiatr Serv 2008, 59:523-525.
8. Clark N.G. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
9. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19:1-93.
10. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62:22-31.
11. Goudie A.J., Cooper D., Halford J.C.G. Antipsychotic-induced weight gain. Diabetes obesity Metabolism 2005, 7:478-487.
12. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
13. Graham K.A., Perkins D.O., Edwards L.J., Barrier R.C., Lieberman J.A., Harp J.B. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005, 162:118-123.
14. Bobes J., Arango C., Aranda P., Carmena C., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 2007, 90:162-173.
15. Osby U., Correira N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county Sweden. Schizophr Res 2000, 45:21-28.
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
17. Vitiello B., Correll C., van Zwieten-Boot B., Zuddas A., Parellada M., Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009, 19:629-635.
18. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
19. Fraguas D., Merchán-Naranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008, 69:1166-1175.
20. Arango C., Robles O., Parellada M., Fraguas D., Ruiz-Sancho A., Medina O., et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009, 18:418-428.
21. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003, 28:519-526.
22. Roerig J.L., Mitchell J.E., Zwaan M., Crosby R.D., Gosnell B.A., Steffen K.J., et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviours. J Clin Psychopharmacol 2005, 25:413-418.
23. Sharpe J.K., Byrne N.M., Stedman T.J., Hills A.P. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005, 105:612-615.
24. Skouroliakou M., Giannopolou I., Kostara C., Vasilopoulou M. Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine. Nutrition 2009, 25:188-193.
25. Sharpe J.K., Stedman T.J., Byrne N.M., Wishart C., Hills A.P. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006, 40:810-814.
26. Virkkunen M., Wahlbeck K., Rissanen A., Naukkarinen H., Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment- a case study. Pharmacopsychiatry 2002, 35:124-126.
27. Procyshyn R.M., Chau A., Tse G. Clozapine's effects on body weight and resting metabolic rate: a case series. Schizophr Res 2004, 66:159-162.
28. Sharpe J.K., Byrne N., Stedman T., Hills A. Atypical antipsychotic medications and symptoms of psychotic illness do not affect resting metabolic rate in people with mental illness. Obes Reviews 2006, 7:159.
29. Castro-Fornieles J., Parellada M., Soutullo C.A., Baeza I., Gonzalez-Pinto A., Graell M., et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 2008, 18:327-336.
30. Lee R.D., Nieman D.C. Anthropometry. Nutritional assessment 1996, 223-288. Mosby-Year Book Inc, St Louis, Missouri. 2nd ed. R.D. Lee, D.C. Nieman (Eds.).
31. Cuerda C., Ruiz A., Moreno C., Iriondo M.T., Velasco C., Bretón I., et al. Study of resting energy expenditure in anorexia nervosa, agreement between indirect calorimetry and several equations. Nutr Hosp 2005, 20:371-377.
32. Bouchard C., Tremblay A., Leblanc C., Lortie G., Savard R., Theriault G. A method to assess energy expenditure in children and adults. Am J Clin Nutr 1983, 37:461-467.
33. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010, 67:255-262.
34. Harris J.A., Benedict F.G. A biometric study of basal metabolism in man 1919, Carnegie Institution of Washington, Washington, DC.
35. Webb P. Energy expenditure and fat-free mass in men and women. Am J Clin Nutr 1981, 34:1816-1826.
36. Schoeller D.A. The importance of clinical research: the role of thermogenesis in human obesity. Am J Clin Nutr 2001, 73:511-516.
37. Bandini L.G., Schoeller D.A., Edwards J., Young V.R., Oh S.H., Dietz W.H. Energy expenditure during carbohydrate overfeeding in opbese and nonobese adolescents. Am J Physiol 1989, 256:E357-E367.
38. Schoeller D.A. Balancing energy expenditure and body weight. Am J Clin Nutr 1998, 68(Suppl.):956S-961S.
39. Leibel R.L., Rosenbaum M., Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995, 332:621-628.
40. Nilsson B.M., Forslund A.H., Olsson R.M., Hambraeus L., Wiesel F.A. Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand 2005, 114:27-35.
41. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
42. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006, 163:1276-1279.
43. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009, 43:620-626.
44. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008, 100:70-85.
45. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006, 20:75-79.
46. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinol 2005, 30:106-110.
47. Murashita M., Inoue T., Kusumi I., Nakagawa S., Itoh K., Tanaka T., et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007, 61:54-58.
48. Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005, 44:925-933.
49. Pérez-Iglesias R., Vázquez-Barquero J.L., Amado J.A., Berja A., García-Unzueta M.T., Pelayo-Terán J.M., et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 2008, 28:289-295.
50. Togo T., Kojima K., Shoji M., Kase A., Uchikado H., Katsuse O., et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004, 19:37-40.
51. Richards A.A., Hickman I.J., Wang A.Y., Jones A.L., Newell F., Mowry B.J., et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006, 26:232-237.
52. Birkenaes A.B., Birkeland K.I., Friis S., Opjordsmoen S., Andreassen O.A. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J Clin Psychopharmacol 2009, 29:109-116.
53. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 106:308-314.
54. Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Liou Y.J., Lin C.C., et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007, 68:1834-1839.
55. Bai Y.M., Chen T.T., Yang W.S., Chi Y.C., Lin C.C., Liou Y.J., et al. Association of adiponectin and metabolic syndrome among patients taking antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8.
56. Oriot P., Feys J.L., Mertens de Wilmars S., Misson A., Ayache L., Fagnart O., et al. Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab 2008, 34:490-496.
57. Sharpe J.K., Byrne N.M., Stedman T.J., Hills A.P. Comparison of clinical body composition methods in people taking weight-inducing atypical antipsychotic medications. Asia Pac J Clin Nutr 2008, 17:573-579.